Drilldown: Medicines
Medicines > classes 
:
Analgesic or
Antidepressant or
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]]
:
Analgesic or
Antidepressant or
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] Use the filters below to narrow your results.
generic:
Agomelatine (1) ·
Amoxapine (1) ·
Butorphanol (1) ·
Clomipramine (1) ·
Codeine (2) ·
Desipramine (1) ·
Dextropropoxyphene (1) ·
Dihydrocodeine (1) ·
Doxazosin (1) ·
Duloxetine (1) ·
Dutasteride (1) ·
Ethylmorphine (1) ·
Fentanyl (1) ·
Finasteride (1) ·
Hydrocodone (1) ·
Hydromorphone (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Levomilnacipran (1) ·
Levorphanol (1) ·
Maprotiline (1) ·
Meperidine (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Nalbuphine (1) ·
Nefazodone (1) ·
Oxymorphone (1) ·
Papaverine (1) ·
Pentazocine (1) ·
Phenelzine (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Sertraline (1) ·
Tamsulosin (1) ·
Tapentadol (1) ·
Terazosin (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trimipramine (1)
brand:
None (6) ·
(multiple, generic dominant) (1) ·
Anafranil (1) ·
Aurorix (1) ·
Avodart; combined with tamsulosin as Jalyn (1) ·
Cardura, Cardura XL (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Darvon (1) ·
Demerol (1) ·
Dilaudid (1) ·
Duragesic (1) ·
Edronax (1) ·
Fetzima (1) ·
Flomax (1) ·
Hytrin (US brand discontinued); mostly generic (1) ·
Ludiomil (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Nubain (1) ·
Nucynta (1) ·
Opana (1) ·
Parnate (1) ·
Proscar (5 mg, BPH), Propecia (1 mg, alopecia) (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Stadol (1) ·
Surmontil (1) ·
Talwin (1) ·
Tofranil (1) ·
Valdoxan (1) ·
Vicodin (1) ·
Vivactil (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (4) ·
Irreversible non-selective MAO inhibitor (3) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (3) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1) ·
'"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
uses:
None (33) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
'"`UNIQ--vote-000001BA-QINU`"', '"`UNIQ--vote-000001BB-QINU`"' (1) ·
'"`UNIQ--vote-0000052E-QINU`"', '"`UNIQ--vote-0000052F-QINU`"', '"`UNIQ--vote-00000530-QINU`"' (1) ·
'"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"' (1) ·
'"`UNIQ--vote-00000D57-QINU`"', '"`UNIQ--vote-00000D58-QINU`"' (1) ·
'"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"' (1)
starting dose:
None (33) ·
0.4 mg PO once daily, 30 minutes after the same meal each day (1) ·
0.5 mg PO once daily (1) ·
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) ·
25 mg (1) ·
5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia (1) ·
Adult: 15–60 mg every 4 hours as needed. (1) ·
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1)
preparations:
None (33) ·
0.4 mg capsules (1) ·
0.5 mg capsules (1) ·
1 mg, 5 mg tablets (1) ·
1, 2, 4, 8 mg IR tablets; 4, 8 mg XL tablets (1) ·
1, 2, 5, 10 mg capsules and tablets (1) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
onset:
None (32) ·
30–60 min (PO) (1) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
BP and symptomatic LUTS improvement within 1-2 weeks (2) ·
BPH symptom improvement at 3-6 months; prostate volume reduction over 6-12 months; hair regrowth at 6-12 months (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) ·
Prostate volume reduction over 6-12 months (1) ·
Symptom improvement within 1 week; peak effect at 4-6 weeks (1)
duration:
halflife:
None (32) ·
2.5–3 hours (1) ·
9-15 hours'"`UNIQ--ref-000001BC-QINU`"' (1) ·
~12 hours (1) ·
~12 hours'"`UNIQ--ref-0000111F-QINU`"' (1) ·
~22 hours'"`UNIQ--ref-00000AB0-QINU`"' (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) ·
~5 weeks (much longer than finasteride's ~6 hours)'"`UNIQ--ref-00000D59-QINU`"' (1) ·
~5-6 hours in young men, ~8 hours in elderly'"`UNIQ--ref-00000531-QINU`"' (1)
bioavailability:
None (32) ·
>90% (oral; food slows absorption and reduces peaks, hence the post-meal dosing rule)'"`UNIQ--ref-000001BD-QINU`"' (1) ·
>90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"' (1) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
~50% (highly variable) (1) ·
~50% (variable, CYP2D6-dependent for analgesic effect). (1) ·
~60% (oral)'"`UNIQ--ref-00000D5A-QINU`"' (1) ·
~63% (oral)'"`UNIQ--ref-00000532-QINU`"' (1) ·
~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"' (1)
pregnancy:
None (32) ·
'''Pregnant individuals should not handle crushed/broken tablets''' (skin absorption risk); can cause hypospadias in male fetus. Not used in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
'''Pregnant individuals should not handle dutasteride capsules''' (skin absorption risk through intact capsule); can cause hypospadias in male fetus.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not applicable (male indication); historical Category B if used in unrelated female cases.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 40 results in range #1 to #40.